Presentation of Endometrial Cancer and MMR Testing
Dr Robert Holloway describes the presentation of a typical patient with metastatic endometrial cancer, and whether all patients receive MMR testing.
Case History
June 2021
A 71-year-old postmenopausal woman presented with intermittent uterine bleeding, increased urinary frequency, and cramping over the past 6 months.
- She noted that she underwent menopause at 52 years of age
- She is married and has 2 adult children
- PMH: T1D since childhood, well-controlled
- PE: Notable for uterine tenderness upon palpation
- ECOG PS= 1
- Chest/abdomen/pelvis CT revealed uterine and bladder masses
- CA-125= 38.6 U/mL
- Endometrial biopsy results:
- Endometrioid adenocarcinoma
- FIGO stage IVA
- Grade 3 (poorly differentiated)
- IHC testing revealed mismatch repair proficiency (pMMR) and estrogen receptor (ER) negativity
July 2021:
- Patient started carboplatin/paclitaxel (6 cycles), which was well-tolerated
- Patient was scheduled for follow-up visits every 3 months after completion
May 2022 (6 months post–chemotherapy completion):
- CA-125 level increased to 42.1 U/mL
- CT revealed that the previous bladder metastatic mass increased slightly in size
- The patient discussed targeted systemic therapy options with her clinician, and she expressed the desire to spend as much time as possible with her grandchildren.
- They jointly decided to trial lenvatinib/pembrolizumab, with instructions to continue follow-up visits every 3 months.
Recent Videos
Related Content
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024Article
The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More
